• Je něco špatně v tomto záznamu ?

TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer

J. Fucikova, J. Rakova, M. Hensler, L. Kasikova, L. Belicova, K. Hladikova, I. Truxova, P. Skapa, J. Laco, L. Pecen, I. Praznovec, MJ. Halaska, T. Brtnicky, R. Kodet, A. Fialova, J. Pineau, A. Gey, E. Tartour, A. Ryska, L. Galluzzi, R. Spisek,

. 2019 ; 25 (15) : 4820-4831. [pub] 20190510

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem, Research Support, U.S. Gov't, Non-P.H.S.

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025731

PURPOSE: In multiple oncological settings, expression of the coinhibitory ligand PD-L1 by malignant cells and tumor infiltration by immune cells expressing coinhibitory receptors such as PD-1, CTLA4, LAG-3, or TIM-3 conveys prognostic or predictive information. Conversely, the impact of these features of the tumor microenvironment on disease outcome among high-grade serous carcinoma (HGSC) patients remains controversial. EXPERIMENTAL DESIGN: We harnessed a retrospective cohort of 80 chemotherapy-naïve HGSC patients to investigate PD-L1 expression and tumor infiltration by CD8+ T cells, CD20+ B cells, DC-LAMP+ dendritic cells as well as by PD-1+, CTLA4+, LAG-3+, and TIM-3+ cells in relation with prognosis and function orientation of the tumor microenvironment. IHC data were complemented with transcriptomic and functional studies on a second prospective cohort of freshly resected HGSC samples. In silico analysis of publicly available RNA expression data from 308 HGSC samples was used as a confirmatory approach. RESULTS: High levels of PD-L1 and high densities of PD-1+ cells in the microenvironment of HGSCs were strongly associated with an immune contexture characterized by a robust TH1 polarization and cytotoxic orientation that enabled superior clinical benefits. Moreover, PD-1+TIM-3+CD8+ T cells presented all features of functional exhaustion and correlated with poor disease outcome. However, although PD-L1 levels and tumor infiltration by TIM-3+ cells improved patient stratification based on the intratumoral abundance of CD8+ T cells, the amount of PD-1+ cells failed to do so. CONCLUSIONS: Our data indicate that PD-L1 and TIM-3 constitute prognostically relevant biomarkers of active and suppressed immune responses against HGSC, respectively.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025731
003      
CZ-PrNML
005      
20201222155402.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/1078-0432.CCR-18-4175 $2 doi
035    __
$a (PubMed)31076549
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Fucikova, Jitka $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. fucikova@sotio.com. Sotio, Prague, Czech Republic.
245    10
$a TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer / $c J. Fucikova, J. Rakova, M. Hensler, L. Kasikova, L. Belicova, K. Hladikova, I. Truxova, P. Skapa, J. Laco, L. Pecen, I. Praznovec, MJ. Halaska, T. Brtnicky, R. Kodet, A. Fialova, J. Pineau, A. Gey, E. Tartour, A. Ryska, L. Galluzzi, R. Spisek,
520    9_
$a PURPOSE: In multiple oncological settings, expression of the coinhibitory ligand PD-L1 by malignant cells and tumor infiltration by immune cells expressing coinhibitory receptors such as PD-1, CTLA4, LAG-3, or TIM-3 conveys prognostic or predictive information. Conversely, the impact of these features of the tumor microenvironment on disease outcome among high-grade serous carcinoma (HGSC) patients remains controversial. EXPERIMENTAL DESIGN: We harnessed a retrospective cohort of 80 chemotherapy-naïve HGSC patients to investigate PD-L1 expression and tumor infiltration by CD8+ T cells, CD20+ B cells, DC-LAMP+ dendritic cells as well as by PD-1+, CTLA4+, LAG-3+, and TIM-3+ cells in relation with prognosis and function orientation of the tumor microenvironment. IHC data were complemented with transcriptomic and functional studies on a second prospective cohort of freshly resected HGSC samples. In silico analysis of publicly available RNA expression data from 308 HGSC samples was used as a confirmatory approach. RESULTS: High levels of PD-L1 and high densities of PD-1+ cells in the microenvironment of HGSCs were strongly associated with an immune contexture characterized by a robust TH1 polarization and cytotoxic orientation that enabled superior clinical benefits. Moreover, PD-1+TIM-3+CD8+ T cells presented all features of functional exhaustion and correlated with poor disease outcome. However, although PD-L1 levels and tumor infiltration by TIM-3+ cells improved patient stratification based on the intratumoral abundance of CD8+ T cells, the amount of PD-1+ cells failed to do so. CONCLUSIONS: Our data indicate that PD-L1 and TIM-3 constitute prognostically relevant biomarkers of active and suppressed immune responses against HGSC, respectively.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antigeny CD274 $x imunologie $x metabolismus $7 D060890
650    _2
$a nádorové biomarkery $x imunologie $x metabolismus $7 D014408
650    _2
$a CD8-pozitivní T-lymfocyty $x imunologie $7 D018414
650    _2
$a antigen CTLA-4 $x imunologie $x metabolismus $7 D060908
650    _2
$a epiteliální ovariální karcinom $x imunologie $x metabolismus $x patologie $7 D000077216
650    _2
$a serózní cystadenokarcinom $x imunologie $x metabolismus $x patologie $7 D018284
650    _2
$a ženské pohlaví $7 D005260
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a buněčný receptor 2 viru hepatitidy A $x imunologie $x metabolismus $7 D000072597
650    _2
$a lidé $7 D006801
650    _2
$a tumor infiltrující lymfocyty $x imunologie $7 D016246
650    _2
$a membránové glykoproteiny asociované s lyzozomy $x imunologie $x metabolismus $7 D051907
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x imunologie $x metabolismus $7 D009363
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Rakova, Jana $u Sotio, Prague, Czech Republic.
700    1_
$a Hensler, Michal $u Sotio, Prague, Czech Republic.
700    1_
$a Kasikova, Lenka $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Sotio, Prague, Czech Republic.
700    1_
$a Belicova, Lucie $u Sotio, Prague, Czech Republic.
700    1_
$a Hladikova, Kamila $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Sotio, Prague, Czech Republic.
700    1_
$a Truxova, Iva $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Sotio, Prague, Czech Republic.
700    1_
$a Skapa, Petr $u Department of Pathology and Molecular Medicine, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Pecen, Ladislav $u Sotio, Prague, Czech Republic.
700    1_
$a Praznovec, Ivan $u Department of Gynecology and Obstetrics, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Halaska, Michael J $u Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
700    1_
$a Brtnicky, Tomas $u Department of Gynecology and Obstetrics, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Kodet, Roman $u Department of Pathology and Molecular Medicine, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.
700    1_
$a Fialova, Anna $u Sotio, Prague, Czech Republic.
700    1_
$a Pineau, Josephine $u INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France. Service d'Immunologie Biologique, AP-HP, Hopital Européen Georges Pompidou, Paris, France.
700    1_
$a Gey, Alain $u INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France. Service d'Immunologie Biologique, AP-HP, Hopital Européen Georges Pompidou, Paris, France.
700    1_
$a Tartour, Eric $u INSERM U970, Université Paris Descartes, Sorbonne Paris-Cité, Paris, France. Service d'Immunologie Biologique, AP-HP, Hopital Européen Georges Pompidou, Paris, France.
700    1_
$a Ryska, Ales $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Czech Republic.
700    1_
$a Galluzzi, Lorenzo $u Department of Radiation Oncology, Weill Cornell Medical College, New York, New York. Sandra and Edward Meyer Cancer Center, New York, New York. Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Université Paris Descartes/Paris V, Paris, France.
700    1_
$a Spisek, Radek $u Department of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. Sotio, Prague, Czech Republic.
773    0_
$w MED00001121 $t Clinical cancer research : an official journal of the American Association for Cancer Research $x 1078-0432 $g Roč. 25, č. 15 (2019), s. 4820-4831
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31076549 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155358 $b ABA008
999    __
$a ok $b bmc $g 1599876 $s 1116417
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 25 $c 15 $d 4820-4831 $e 20190510 $i 1078-0432 $m Clinical cancer research $n Clin Cancer Res $x MED00001121
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace